Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 6/20 | 0.39 |
| ▸ | SYK | P43405 | 3/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 5/20 | 0.34 |
| ▸ | JAK3 | P52333 | 5/20 | 0.34 |
| ▸ | JAK1 | P23458 | 4/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24284139 | 0.83 | CCNB2 (0.34) | MAPK1SYKPDK2PDK4MET | |
| SCHEMBL25851514 | 0.80 | MAPK1 (0.37) | MAPK1SYKPDK2PDK4JAK2 | |
| SCHEMBL13199608 | 0.80 | JAK2 (0.40) | MAPK1SYKPDK2PDK4JAK2 | |
| SCHEMBL20846079 | 0.80 | ALDH1A1 (0.41) | MAPK1SYKJAK2JAK3JAK1 | |
| SCHEMBL2378181 | 0.80 | MAPK1 (0.62) | MAPK1SYKJAK2JAK3JAK1 | |
| SCHEMBL16946856 | 0.80 | MAPK1 (0.37) | MAPK1SYKPDK2PDK4JAK2 | |
| SCHEMBL14616216 | 0.80 | MAPK1 (0.62) | MAPK1SYKPDK2PDK4JAK2 | |
| SCHEMBL21941202 | 0.80 | MAPK1 (0.37) | MAPK1SYKJAK2JAK3JAK1 | |
| SCHEMBL22201885 | 0.77 | SYK (0.39) | MAPK1SYKPDK2PDK4JAK2 | |
| SCHEMBL16186593 | 0.77 | PDPK1 (0.35) | MAPK1JAK2JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| US-20210253571-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | WUXI LIFE FOUNTAIN BIOTECH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| EP-3825314-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | Medshine Discovery Inc. (CN) | 2021-05-26 | — | — | EP | disclosed |
| EP-3317285-B1 | CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TURNING POINT THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2020264420-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-3636650-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3636649-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2020015744-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | 南京明德新药研发有限公司 | 2020-01-23 | — | — | WO | disclosed |
| EP-3097107-B1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
| US-9714258-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-9309250-B2 | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-12 | — | — | US | disclosed |
| US-8822469-B2 | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130034616-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130018035-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-17 | — | — | US | disclosed |
| US-20110130384-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-02 | — | — | US | disclosed |
| US-20110130384-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-02 | — | — | US | disclosed |
| EP-2298731-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009157196-A1 | AMIDE COMPOUND | 武田薬品工業株式会社 (JP) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018035-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | MAPK1 122/4885SYK 495/4885PDK2 380/4885 |
| US-20110130384-A1 | AMIDE COMPOUND | GPR52, CNR2, ARRB1 | MAPK1 1313/4885SYK 1506/4885PDK2 4046/4885 |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | MAPK1 82/4885SYK 394/4885PDK2 562/4885 |
| US-20210253571-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | MET, FGFR1, FGFR2 | MAPK1 375/4885SYK 77/4885PDK2 1267/4885 |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | MAPK1 82/4885SYK 394/4885PDK2 562/4885 |
| US-20130034616-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | MAPK1 122/4885SYK 495/4885PDK2 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.